IMMUCYST 81 MG — DIN 02194376
BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT : 81 MG · SANOFI PASTEUR LIMITED · POWDER FOR SUSPENSION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is IMMUCYST?
IMMUCYST 81 MG contains BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT : 81 MG. It is listed in the Health Canada Drug Product Database under DIN 02194376, held by SANOFI PASTEUR LIMITED, supplied as POWDER FOR SUSPENSION for INTRAVESICAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Jan-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is IMMUCYST used for?
Treatment/prophylaxis of carcinoma in situ (CIS) of the urinary bladder and prophylaxis of stage Ta and/or T1 papillary tumours following transurethral resection (TUR).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Bcg Vaccine cost around the world?
Bcg Vaccine is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Hungary | producer price (ex-factory) | 6 | 7 |
| Greece | producer price (ex-factory) | 1 | 1 |
8 pack listings across 7 brand entries and 1 price bases, refreshed 03 Sep 2026. Ranges span every Bcg Vaccine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Bcg Vaccine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Bcg Vaccine, across 5 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MERCK CANADA INC | 1 | 1 | ONCOTICE | Sourceable in Canada |
| VERITY PHARMACEUTICALS INC. | 1 | 1 | VERITY-BCG | Sourceable in Canada |
| CONNAUGHT LABORATORIES LTD. | 1 | 0 | BCG THERAPEUTIC | No marketed DIN |
| ID BIOMEDICAL CORPORATION OF QUEBEC | 1 | 0 | PACIS | No marketed DIN |
| SANOFI PASTEUR LIMITED | 1 | 0 | IMMUCYST | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 81 MG |
|---|---|
| Dosage form | POWDER FOR SUSPENSION |
| Route | INTRAVESICAL |
| Pack configuration (monograph) | Not explicitly detailed in text beyond "vial" with a natural latex rubber stopper. |
| Storage | Not specified in the provided text (refer to "HOW TO STORE IT" section 23 which is not fully detailed in the snippet). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Bcg Vaccine |
|---|---|
| ATC code | L03AX03 |
| AHFS class | 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02194376 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2194376 |
| Brand name | IMMUCYST |
| Generic / active ingredient | BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT : 81 MG |
| Market authorization holder | SANOFI PASTEUR LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L03AX03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L03AX |
| Current status | CANCELLED POST MARKET |
| Status date | 31-Jan-2018 |
| Original market date | 1990-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Intravesical instillation only. Reconstituted 81 mg dose retained in bladder for up to 2 hours. Induction and maintenance schedules used. Do not inject SC, ID, or IV.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; active tuberculosis; history of systemic BCG reaction; febrile illness, UTI, or gross hematuria; immune deficiencies; within 14 days of biopsy, TUR, or traumatic catheterization.
Warnings and precautions
Serious systemic BCG reactions (may be fatal); handle as infectious; risk of ectopic infection in patients with prosthetic devices; avoid trauma to urinary tract.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ONCOTICE | 800000000 UNIT | POWDER FOR SOLUTION | MERCK CANADA INC | MARKETED | 02153513 |
| VERITY-BCG | 40 MG | POWDER FOR SUSPENSION | VERITY PHARMACEUTICALS INC. | MARKETED | 02508613 |
| BCG THERAPEUTIC | 27 MG | POWDER FOR SOLUTION | CONNAUGHT LABORATORIES LTD. | CANCELLED POST MARKET | 00884308 |
| PACIS | 120 MG | POWDER FOR SOLUTION | ID BIOMEDICAL CORPORATION OF QUEBEC | CANCELLED POST MARKET | 02130947 |
2 · Same class — other molecules in ATC L03AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Glatiramer Acetate | COPAXONE · GLATECT · GLATIRAMER ACETATE INJECTION · TEVA-GLATIRAMER ACETATE | 8 | 4 | Yes |
| Bcg Vaccine | BCG THERAPEUTIC · IMMUCYST · ONCOTICE · PACIS · +1 more | 5 | 2 | Yes |
| Plerixafor | MOZOBIL · PLERIXAFOR INJECTION | 4 | 2 | Yes |
| Melanoma Vaccine | MELACINE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L03AA | Ancestim · Filgrastim · Pegfilgrastim | 24 | 21 |
| L03AB | Interferon Alfa-2a · Interferon Alfa-2b · Interferon Alfa-N1 · Interferon Alfacon-1 · Interferon Beta-1a · +6 more | 68 | 9 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.